631 related articles for article (PubMed ID: 33197757)
1. Is the anticonvulsant activity of levetiracetam dose-dependent?
Lamouret V; Kurth C; Intravooth T; Steinhoff BJ
Seizure; 2020 Dec; 83():197-202. PubMed ID: 33197757
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam in toxic seizures.
Lee T; Warrick BJ; Sarangarm P; Alunday RL; Bussmann S; Smolinske SC; Seifert SA
Clin Toxicol (Phila); 2018 Mar; 56(3):175-181. PubMed ID: 28753046
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
[TBL] [Abstract][Full Text] [Related]
5. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.
Abdelmesih SK; Elkhateeb N; Zakaria M; Girgis MY
Seizure; 2021 Oct; 91():263-270. PubMed ID: 34246881
[TBL] [Abstract][Full Text] [Related]
6. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea.
Lee SK; Lee SA; Kim DW; Loesch C; Pelgrims B; Osakabe T; Lee B;
Epilepsy Behav; 2019 Aug; 97():67-74. PubMed ID: 31195326
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical effects of levetiracetam in people with epilepsy with rhythmic epileptiform discharges.
Takebayashi Y; Neshige S; Shishido T; Hayashi Y; Segawa A; Nakamori M; Nezu T; Aoki S; Yamazaki Y; Ueno H; Ohshita T; Iida K; Maruyama H
Epilepsy Behav; 2023 Jun; 143():109225. PubMed ID: 37130461
[TBL] [Abstract][Full Text] [Related]
9. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Stepanova D; Beran RG
Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
[TBL] [Abstract][Full Text] [Related]
10. Equipotency of lacosamide to levetiracetam in new onset focal epilepsy: A randomized controlled trial.
Jaiswal BK; Bhoi SK; Jha M; Samal P; Porey C
J Neurosci Rural Pract; 2023; 14(4):622-628. PubMed ID: 38059231
[TBL] [Abstract][Full Text] [Related]
11. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
12. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
Stephen LJ; Kelly K; Parker P; Brodie MJ
Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
[TBL] [Abstract][Full Text] [Related]
14. The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.
Gulcebi MI; Kendirli T; Turgan ZA; Patsalos PN; Onat Yilmaz F
Epilepsy Res; 2018 Dec; 148():17-22. PubMed ID: 30326332
[TBL] [Abstract][Full Text] [Related]
15. Temporal relationship between levetiracetam nonadherence and breakthrough seizures in a preclinical model of temporal lobe epilepsy.
Guignet M; Vuong J; Martinez A; Ballapapinan T; White HS
Epilepsia; 2024 Feb; 65(2):497-510. PubMed ID: 38031477
[TBL] [Abstract][Full Text] [Related]
16. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
[TBL] [Abstract][Full Text] [Related]
18. Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy.
Schelhaas M; Wegner I; Edens M; Wammes-Van Der Heijden E; Touw D; Ter Horst P
Neurology; 2023 Jan; 100(2):e172-e181. PubMed ID: 36257713
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center.
Yıldırım M; Bektaş Ö; Akıncı Göktaş Ö; Yüksel MF; Şahin S; Tıraş Teber S
Epilepsy Behav; 2021 Mar; 116():107745. PubMed ID: 33508749
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
